Topic: Combination Treatment of Hutchinson Gilford Progeria Syndrome
Speaker: Elena Vehns, Djabali Group
Date and Time: Tuesday, 20 June 2021, 1:00 pm
Abstract: Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging disease. Worldwide approximately 20 million people are affected from this disease. This syndrome is caused by a mutation in the LMNA gene, resulting in a permanently farnesylated and carboxymethylated protein called progerin. HGPS patients develop several features of physiological aging including arthritis and atherosclerosis. Since there is no cure for this disease, we are working on a novel therapeutic treatment option for HGPS. Therefore, we combined two drugs with different modes of action to find out whether they had a synergistic effect.
FURTHER PROGRAM SUMMER TERM 2021
The seminar series has come to an end for this semester and will start again October 2021.